Uninsured patients have decreased access to care, lower rates of percutaneous coronary intervention (PCI), and worse outcomes after acute myocardial infarction (AMI).

Online Resource

New York : Springer, [2007]

Wills, B. A. (Barry Alan)

Wills, B. A. (Barry Alan)

Wills, B. A. (Barry Alan), author

Increased attention has focused on shared decision-making (SDM) and use of decision aids for treatment decisions in cardiology. In this issue of JAMA Cardiology, Coylewright et al report the results of a rigorously performed pilot study on the use of a decision aid to facilitate SDM for patients with symptomatic severe aortic stenosis (AS) at high or prohibitive risk for surgery considered for transcatheter aortic valve replacement vs medical therapy. Comparisons were made between encounters before clinicians were trained to use a decision aid and the first and fifth encounters after a decision aid was used. The patient-clinician interactions were audio recorded and later coded by independent reviewers using a validated measure to assess SDM. This mixed-methods study found that SDM significantly improved in a stepwise manner from the initial usual care encounter (before use of a decision aid) to the first and then fifth encounters after implementation of the decision aid. Along with this improvement in SDM, patients (n = 35) demonstrated increased knowledge about their treatment choices and reported increased satisfaction in their care with no increase in decisional conflict. In contrast, clinicians (n = 6) reported that they believed they already engaged in SDM prior to use of the decision aid and, after multiple uses of the decision aid, believed patients did not understand or benefit from this tool. The disconnect between clinician and patient perspectives was sobering and has implications for the adoption of decision aids or other tools to facilitate SDM in the clinical setting. Notable limitations of the study, which are acknowledged by the authors, include (1) small sample size (of clinicians and patients); (2) the decision aid is most useful for the relatively smaller number of patients at high or prohibitive risk for surgery for whom transcatheter aortic valve replacement and medical therapy may both be reasonable options; and (3) the lack of diversity in the clinicians (all male), which reflects the current demographics of interventional cardiology and cardiac surgery.

Stefanakis, Alexandros, 1982-

Weaver, John, 1980- author

Interview with Francesca Gay, author of Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

Interview with Brooke Nickel and Juan Brito, MD, MSc, authors of Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences: A Randomized Crossover Trial

Interview with Ananias C Diokno, MD, author of Effect of Group-Administered Behavioral Treatment on Urinary Incontinence in Older Women: A Randomized Clinical Trial

Interview with Andreas Walther, PhD, author of Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis

Interview with David Urbach, author of The Role of Disease Label in Patient Perceptions and Treatment Decisions in the Setting of Low-Risk Malignant Neoplasms

Interview with Katy J.L. Bell, PhD, author of Patients’ Views About Skin Self-examination After Treatment for Localized Melanoma

Interview with Klaus Wölfling, PhD, author of Efficacy of Short-term Treatment of Internet and Computer Game Addiction: A Randomized Clinical Trial

Interview with David J. Pinato, MD, author of Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Interview with Alexander Gelbard, MD, author of Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis

Interview with John Sims, author of Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials

Wang, Wei, 1972 September-- author

Gilead has a head start on an antiviral, while Moderna is pursuing a novel mRNA vaccine

Gilead has a head start on an antiviral, while Moderna is pursuing a novel mRNA vaccine

Many are FDA-approved drugs that could be repurposed

Japanese government plans to buy at least 2 million tablets of the influenza drug

Japanese government plans to buy at least 2 million courses of the influenza drug

A new disinfection chemistry holds environmental and financial promise

Method exchanges framework linkers with others that cannot be incorporated via traditional synthesis techniques

Tokyo ; New York : Springer, [2006]

Totowa, N.J. : Humana Press, c2007